James W. Larrick

top barjimpic








Dr. Larrick’s main focus is protein therapeutics, but his research breadth covers a diverse range of scientific disciplines to create novel therapeutic candidates. His is a leading expert in the research of: sepsis, innate and adaptive immunity, antibody therapeutics, antibody humanization, biology of human aging,

Dr. James Larrick is a biomedical entrepreneur with an international reputation in biotechnology [cytokines, therapeutic antibodies, molecular biology, pharmaceutical drug development] having written or co-authored eight books, over 250 papers/chapters and >forty patents in his twenty-five year career. He has served on the editorial board of six journals. Dr. Larrick’s work on therapeutic antibodies and other protein therapeutics has spanned the whole range of biopharmaceutical product development from target discovery, process science to clinical trials. Dr. Larrick received his MD and PhD. degrees from Duke University School of Medicine. He trained at Stanford and was then a founding scientist at Cetus Immune where he became Director of Research. In 1992, Dr. Larrick founded the non-profit Panorama Institute of Molecular Medicine, and Panorama Research Inc., a biotech incubator. Dr. Larrick’s team has discovered developed a diverse, and innovative portfolio of pharmaceutical molecules addressing major unmet needs in cancer, infectious, autoimmune, cardiovascular, neurological and metabolic diseases. PRI has incubated >20 life science companies,. including Kalobios, Absalus Inc. (now Teva Inc.), Galaxy Biotech, and TransTarget Inc. Dr. Larrick has been a member of angel groups and serves as a managing director and Chief Medical Officer of Velocity Pharmaceutical Development LLC in S. San Francisco.

BA, chemistry, Colorado College
MD, PhD, membrane chemistry, Duke University Medical School

Select list from over 250 papers.

  • Follow RSI on social media